A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Part of paid clinical trials in New York, New York.

Sponsor
Pfizer
Study ID
NCT05932290
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Weeks - N/A
Healthy Volunteers
Not accepted

Interventions

  • Elranatamab — DRUG
    BCMA-CD3 bispecific antibody
  • Standard of care — DRUG
    Standard of care

Study Details

This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, the investigators will use data from the phase 2 clinical trial (MagnetisMM-3). The investigators will also use data from multiple real-world sources, representing the SOC in clinical practice. This study does not seek any participants for enrollment. The investigators will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help the investigators to know how well elranatamab can be used for RRMM treatment.

Key Dates

Start date
Jun 1, 2023
Status verified
Oct 2024
Primary completion
Jul 12, 2023
Completion
Jul 12, 2023

Study Design

Enrollment
514 participants (actual)

Arms

  • Arm: Elranatamab
    Patients treated with elranatamab from the MagnetisMM-3 trial
  • Arm: Standard of care
    Patients treated with standard-of-care therapies from real-world data sources

Primary Outcome Measure

Progression Free Survival (PFS): Study C1071003 Cohort A Versus RWD COTA Cohort- Using Unweighted Analysis [ Time Frame: C1071003:First dose to confirmed PD/ death due to any cause or censoring whichever occurred first (maximum of 15 months);COTA:Initiation of first line post TCR MM to PD/ death due to any cause or censoring whichever occurred first (maximum of 64.3 months) ]

Locations (1)

FacilityCityStateZIPSite coordinators
PfizerNew YorkNew York10001-

Find similar trials in New York, NY

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Pfizer· New York, NY

Related Studies